For patients with high-risk resected and advanced melanoma, accurate, timely, and reliable identification of BRAF mutations is essential to ensure appropriate disease management. High-risk resected melanoma includes stage IIC, stage IIIB, and stage IIIC. Advanced melanoma includes unresectable stage III and stage IV. According to the ESMO Guidelines, “mutation testing for actionable mutations is mandatory in patients with resectable or unresectable stage III or stage IV, and is highly recommended in high-risk resected disease stage IIC but not for stage I or stage IIA–IIB).”
Here you’ll find information on the role of BRAF and the MAP kinase (MAPK) pathway, types of BRAF mutations and their role in the development and progression of melanoma, and an overview of BRAF inhibitor treatment.